article Open AccessTop 1% cited

Clinical trial: lubiprostone in patients with constipation‐associated irritable bowel syndrome – results of two randomized, placebo‐controlled studies

Alimentary Pharmacology & Therapeutics · 2008 · Vol. 29(3) · pp. 329–341

Douglas A. Drossman✉(University of North Carolina at Chapel Hill)William D. Chey(Michigan Medicine)John F. Johanson(University of Illinois Chicago)Ronnie Fass(University of Arizona)Charles ScottRaymond M. PanasRyuji Ueno

View via DOI Publisher page

Abstract

The percentage of overall responders based on patient-rated assessments of IBS-C symptoms was significantly improved in patients treated with lubiprostone 8 mcg twice daily compared to those treated with placebo. Lubiprostone was well tolerated with a favourable safety profile.

Gastrointestinal motility and disorders Congenital gastrointestinal and neural anomalies Gastroesophageal reflux and treatmentsLubiprostoneMedicinePlaceboIrritable bowel syndromeInternal medicineConstipationGastroenterologyClinical endpointAdverse effectRandomized controlled trial

MeSH terms

LubiprostoneAdministration, OralAdolescentAdultAgedAged, 80 and overAlprostadilConstipationDefecationFemaleFollow-Up StudiesGastrointestinal AgentsHumansMaleMiddle Aged